Affymetrix Shares Fall on Analyst Downgrade

An analyst from Barclay's Capital downgraded the firm based on a recent influx of competing technologies for sequencing and gene expression analysis.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.